                                  DC REGULATIONS

GENERAL PROVISIONS (ยง 17-8300)

8300.1. Effective, October 1, 2008, this chapter shall apply to applicants for
   and holders of a license to practice pharmaceutical detailing.

   8300.2. Effective April 1, 2009, a person shall be licensed under the Act
   before the individual may practice pharmaceutical detailing in the District of
   Columbia.

   8300.3. A person who practices pharmaceutical detailing in the District of
   Columbia without a license shall be subject to a fine of up to ten thousand
   dollars ($10,000.00) in addition to the other penalties and sanctions set
   forth in the Act and the HORA.

   8300.4. Chapters 40 (Health Occupations: General Rules), and 41 (Health
   Occupations: Administrative Procedures) of this title shall supplement this
   chapter.
   
   
   
   8300.5 	For purposes of this chapter, an individual shall be deemed as
   engaging
   
   	 	  in the practice of pharmaceutical detailing if:
   
   
   
   
   
   
   
   He or she is acting as a representative of a pharmaceutical manufacturer or
   
   labeler; and
   
   
   
   
   
   
   
   Communicating in person with a licensed health professional or an employee
   
   or representative of a licensed health professional located in the District of
   
   Columbia;
   
   
   
   
   
   
   
   In a non-conference setting, as defined in this chapter;
   
   
   
   
   
   
   
   For the purpose of selling, marketing, or promoting a prescription or
   over-the-counter pharmaceutical product for use in humans, or providing
   information about a pharmaceutical product for the purpose of selling,
   marketing, or promoting such product.

   8300.6. The scope of this chapter shall not apply to representatives who only
   sell, market, or promote veterinary drugs.

   8300.7. The scope of this chapter shall not apply to the act of providing
   information about a pharmaceutical product solely for the purpose of
   conducting or pertaining to clinical trials, investigational drugs, or a Risk
   Evaluation and Mitigation Strategy pursuant to the Federal Food, Drug and
   Cosmetic Act.

   8300.8. The scope of this chapter shall not apply to activities taking place
   at a conference, as defined in   this chapter.

   8300.9. The scope of this chapter shall not apply to health professionals 
   participating in a conference, as defined in this chapter, including
   conferences targeting a local audience, solely as a speaker or presenter with
   respect to his or her area of expertise.
   
   
   
   
   
   	SOURCE: Final Rulemaking published at 55 DCR 9317 (August 29, 2008); as
   amended by Final Rulemaking published at 56 DCR 2951 (April 17, 2009).
